Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | HTR5A | P47898 | 1/20 | 0.33 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21596915 | 0.76 | PARP1 (0.41) | ACHEPARP1 | |
| SCHEMBL21596942 | 0.76 | BACE1 (0.40) | TYMS | |
| SCHEMBL21596933 | 0.76 | BRD4 (0.38) | — | |
| SCHEMBL15924952 | 0.72 | — | — | |
| SCHEMBL21596923 | 0.72 | ELANE (0.35) | TYMS | |
| SCHEMBL21596932 | 0.72 | DCPS (0.51) | ACHERPS6KA2HTR5A | |
| SCHEMBL21596907 | 0.69 | TYMS (0.43) | TYMS | |
| SCHEMBL21596935 | 0.68 | ALDH1A1 (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1781743 | 0.68 | KDR (0.54) | — | |
| SCHEMBL1013979 | 0.66 | ALDH1A1 (0.44) | ACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3810602-A1 | COMPOUNDS | CTXT Pty Limited (AU) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019243491-A1 | COMPOUNDS | CTXT PTY LIMITED (AU) | 2019-12-26 | — | — | WO | disclosed |
| WO-2009046536-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2009-04-16 | — | — | WO | disclosed |
| US-7410974-B2 | Halogenated Quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) | 2008-08-12 | — | — | US | disclosed |
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC., | 2008-06-19 | — | — | US | disclosed |
| EP-1660486-A4 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCT (CA) | 2006-12-13 | — | — | EP | disclosed |
| US-20060258693-A1 | Halogenated quinazolinyl nitrofurans as antibacterial agents | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-1660486-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | Ulysses Pharmaceuticals Products Inc. (CA) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014585-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146562-A1 | HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS | HRH3, HRH1, NQO2 | ACHE 4534/4885PARP1 2980/4885TYMS 2570/4885 |
| US-20060258693-A1 | Halogenated quinazolinyl nitrofurans as antibacterial agents | C1S, HRH1, NQO2 | ACHE 4144/4885PARP1 2237/4885TYMS 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.